Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Mar 22, 2016 3:33pm
369 Views
Post# 24689402

RE:RE:great follow on news....

RE:RE:great follow on news....
Youre exactly right,   the rubber really hits the road with the double blind / placebo pivotal trials.  But this data is very compelling.  Everything is pointing to the same conclusion,  that the efficacy seen in the animal model translates to humans,  and perhaps even more importantly,  this lends credence to the likelihood of human efficacy in the other anti-fibrotic related indications...  its HUGE. ...   This makes the CDN Open label IPF trial results due mid year even more important ....and who knows what surprises are in store.

I thought it interesting to see the normally conservative Cannacord analyst specifically referencing Big Pharma action may be heating up as well.

regardless,  short of a broader market meltdown,  the company is doing nothign to aid the building short position find a way out.   They arent slipping up, in fact they are turning up the heat.... which should theoretically increase institutional buy-in.   I would sure love to see the Piper Jaffray analyst or another meaningful US Analyst pick up coverage... 


Bullboard Posts